Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

Subjects:

The body weight and cholesterol levels of the mice were recorded before the administration of the drug. by Xueqin lu (22250795)

Subjects:

The trends of cholesterol metabolism-related gene expression in liver tissue. by Xueqin lu (22250795)

Subjects:

Kylo-0603’s EC50 & tissue levels. by Xueqin lu (22250795)

Subjects:

DIO Mice Liver Staining. by Xueqin lu (22250795)

Subjects:

The Fibrosis scoring by Sirius Red staining and SHG/TPEF. by Xueqin lu (22250795)

Subjects:

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Subjects:

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Subjects:

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

Subjects:

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

Subjects:

Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... by Xueqin lu (22250795)

Subjects:

Effect of Kylo-0603 drug on the reversal of steatosis and inhibition of fibrotic process in liver tissues of the MASH mouse models (F2 ~ 3), analyzed by SHG/TPEF microscopy combine... by Xueqin lu (22250795)

Subjects:

S1 Data - by Miki Doi (15347878)

Subjects:

S1 Fig - by Miki Doi (15347878)

Subjects:

General procedure for the synthesis of Kylo-0603. by Xueqin lu (22250795)

Subjects:

Fig 6 - by Keith Fraser (1868587)

Subjects:

Fig 7 - by Keith Fraser (1868587)

Subjects:

Modelled seroprevalence estimates (coloured regions) compared with real data (black). by Keith Fraser (1868587)

Subjects:

Table of parameters. by Keith Fraser (1868587)

Subjects:

Semiannual analysis of monthly use of sterile blood transfer devices. by Miki Doi (15347878)

Subjects: